Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States
Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States
Stefano Lucherini, Ariel Sun, Sandra Milev, Reginald Villacorta et al.
Journal
Journal of Medical Economics
Topics
Lung Cancer Diagnosis and Treatment
article
Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States
Stefano Lucherini, Ariel Sun, Sandra Milev, Reginald Villacorta, Benjamin White, M. Harris